Investor Relations

High-growth company with focus on becoming a single-use pure player within all main endoscopy markets.

Latest news

09

Feb. 2024

Reporting of transactions made by persons discharging managerial responsibilities (no 9)

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.  

The attached document discloses the data of the transactions made in Ambu shares. 

Attachment: 09_02_2024 Henrik Skak Bender

 

ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific.

06

Feb. 2024

Grant of performance share units (no 8)

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.

The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT margin) for the fiscal year 2023/24 and will be within the range of
0-200% of the initial grant.

The PSUs are granted free and subject to achievement of the KPIs mentioned above. Each PSU will at vesting, on 1 January 2027, be converted to one Class B share in Ambu A/S subject to the terms of the LTIP.

The average price applied to calculate the number of PSUs is the average price quoted by NASDAQ Copenhagen in respect of Ambu A/S Class B shares on the day of the Annual General Meeting and the subsequent four (4) trading days (13-19
December 2023).

The value of the PSUs will, at the time of vesting, be capped at four times the annual base salary of the individual participant measured at the time of the grant.
 

ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific.



Read the full company announcement here.

30

Jan. 2024

Interim report for Q1 2023/24 (no 7)

In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%.

“I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start to meet our financial guidance for this fiscal year.

Whereas the first year of our transformative ZOOM IN strategy revolved around re-building our financial foundation, this second year is dedicated to accelerated growth at higher margins. I am excited to continue our trajectory along with my dedicated colleagues at Ambu, to support our customers and their patients, all over the world.”

Britt Meelby Jensen
Chief Executive Officer

 

HIGHLIGHTS FOR THE QUARTER

Last year’s comparative figures are presented in brackets.

Financial highlights

  • Revenue for Q1 increased organically by 14% (4%) to DKK 1,254m (DKK 1,132m). Reported growth for the quarter was 11% (10%).
  • Endoscopy Solutions increased organically by 25% (3%). Pulmonology posted 18% (-17%) organic growth, and Endoscopy Solutions excl. pulmonology posted 34% (47%) organic growth, driven by strong growth in urology and ENT.
  • Anaesthesia & Patient Monitoring increased organically by 1% (5%), combined. Both were affected by price increases in selected low-margin areas, which is implemented on a rolling basis throughout the financial year.
  • EBIT before special items for the quarter was DKK 126m (DKK 68m), with an EBIT margin before special items of 10.0% (6.0%). The improved EBIT margin of 4.0 %-pts was mainly driven by revenue expansion driving scale in OPEX of 3.6 %-pts, while operational expenses plateaued. The impact of foreign exchange rates on the EBIT margin was approximately +1%-pts.
  • Free cash flow before acquisitions totalled DKK 135m (DKK -174m) for the quarter, driven by improved EBITDA, net working capital and lower CAPEX.
  • The FY 2023/24 financial guidance stated on 8 November 2023 is maintained:
    • Organic revenue growth: 7-10%
    • EBIT margin before special items: 8-10%

Business highlights

  • Strengthened urology offering with European regulatory clearance (CE mark) of aScope™ 5 Uretero and aScope™ Cysto 5 HD.
  • Ambu’s near-term climate targets validated by SBTi, reflecting the reduction of absolute scope 1 and 2 greenhouse gas emissions by 75% by the 2029/30 financial year. Also, ambition set to reach net-zero emissions across the value chain by 2045.
  • Completion of Executive Leadership Team, with Henrik Bender (CFO) on-boarded and Rummana Hasan appointed as Chief Marketing Officer (CMO) as of 1 February 2024.

 

Q1 2023/24 CONFERENCE CALL

A conference call is broadcast live today, Tuesday 30 January 2024, at 11:00 (CET), via Ambu.com/webcastQ12024. To ask questions during the Q&A session, please register prior to the call via Ambu.com//conferencecallQ12024register. Upon registration, you will receive an e-mail with the needed information to access the call.

The presentation can be downloaded at Ambu.com/presentations.

 

ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,600 people in Europe, North America, Latin America and Asia Pacific.

For more information, please visit Ambu.com.

 

Read the ful Q1 2023/24 report here.

 

CONTACT

Investors
Anders Hjort
Head of Investor Relations
anhj@ambu.com
+45 2892 8881

Media
Tine Bjørn Schmidt
Head of Corporate Communications
tisc@ambu.com
+45 2264 0697

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Upcoming events

14

May. 2024

Earnings release Q2 2023/24

30

Aug. 2024

Earnings release Q3 2023/24

30

Sep. 2024

End of fiscal year 2023/24

News from Ambu

Sign up and receive financial news and company announcements from Ambu

Sign up

 

keyboard_arrow_up